Ellagic acid Cancer Research Results

EA, Ellagic acid: Click to Expand ⟱
Features:
Polyphenol found in fruits, vegetables, nuts and some mushrooms. Strawberries, raspberries, blackberries, cherries and walnuts, green tea and red wine. Pomegranate arils are a well known source.
Ellagic acid (EA) is a dietary polyphenol found in berries and pomegranate-related foods, with reported anti-inflammatory (NF-κB↓), survival-pathway suppression (PI3K/AKT↓), and anti-proliferative effects including G1 arrest and apoptosis in many cancer models. A key practical nuance is that EA/ellagitannins are extensively transformed by gut microbiota into urolithins, which are more bioavailable and may account for a large share of systemic effects.

- Ellagitannins are high molecular weight polyphenols with a complex structure that includes one or more HHDP groups attached to a sugar.
- Ellagic Acid is the simpler, bioactive compound released when the HHDP groups in ellagitannins cyclize during hydrolysis.
- one best source is raspberries. 100g gives ~50mg(reasonable dose)
- Ellagic acid has very poor oral bioavailability
- Peak plasma EA after high oral intake is typically: <50–100 nM, often much lower, this is far below concentrations used in many in-vitro anticancer studies (5–50 µM).
- efficacy depends on gut metabolism (ie ability to produce Urolithin A)
- also look at Urolithin supplements

Pathways:
Apoptosis Regulation: (Bax, Bad) (Bcl-2, Bcl-xL)
Cell Cycle Arrest: G0/G1 or G2/M phases)
NF-κB (inhibit):
MAPK Pathways: (including ERK1/2, JNK, and p38 MAPK)
PI3K/Akt/mTOR: might downregulate this pathway
p53 Pathway: may influence the expression or activation of p53
Oxidative Stress and Nrf2 Pathway:exhibits antioxidant properties,
Summary:
- Anti-oxidant and metal chelating
- with some evidence it can induce ROS in cancer tumor conditions (mitochondrial stress, redox-unstable cells)
- reported synergy with Curcumin
- Reported, reduced the viability of cancer cells at a concentration of 10 µmol/L, while in healthy cells, this effect was observed only at a concentration of 200 µmol/L
- Pomegranate juice (PJ) (180 ml) containing EA (25 mg) and ETs (318 mg, as punicalagins, the major fruit ellagitannin). Plasma concentration (31.9 ng/ml) after 1 h post-ingestion but was rapidly eliminated by 4 h. (Hence might be difficult to consume enough EA!!!! to match vitro requirements)
- Increased the expression of p53 and p21 proteins as well as markers of apoptosis (Bax and caspase-3), and decreases Bcl-2, NF-кB, and iNOS
- EA has restricted bioavailability, primarily due to its hydrophobic nature and very low water solubility.
- Processing methods can alter EA content; peel extraction often increases measured EA, while prolonged storage/freezing may reduce levels.

Total ellagic acid equivalents (free + bound).
Punica granatum L. Pomegranate 700mg/kg (arils), 38700mg/kg(mesocarp)
Rubus idaeus L. Raspberry 2637–3309mg/kg
jaglandaceae Walnut 410mg/kg(freeEA) 8230mg/kg(totalEA)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 NF-κB inflammatory transcription NF-κB ↓; pro-inflammatory cytokine programs ↓ (context) Inflammation tone ↓ R, G Anti-inflammatory / anti-survival transcription EA is repeatedly reported to suppress NF-κB activity and reduce inflammatory cytokine expression in tumor and inflammation models.
2 PI3K → AKT (± mTOR) survival axis PI3K/AKT ↓ (reported); proliferation ↓ ↔ R, G Growth/survival suppression Multiple cancer studies/reviews report EA-associated suppression of PI3K/AKT signaling linked to G1 arrest and apoptosis.
3 Cell-cycle control (G1 arrest emphasis) Cell-cycle arrest ↑ (often G1); Cyclin/CDK programs ↓ (context) ↔ G Cytostasis Frequently observed as a later phenotype-level outcome; commonly reported alongside reduced proliferation.
4 Intrinsic apoptosis (mitochondrial / caspase-linked) Apoptosis ↑; caspase activation ↑ (context) ↔ (generally less activation) G Apoptosis execution Often downstream of survival signaling suppression and/or stress signaling; reported across multiple tumor types.
5 Nrf2 antioxidant response (Keap1/Nrf2/ARE) Stress adaptation modulation (context-dependent) Nrf2 ↑; antioxidant enzymes ↑ (context) R, G Endogenous antioxidant upshift EA is commonly described as activating Nrf2/ARE programs in oxidative-stress models; tumor direction is model-dependent and should not be overstated.
6 ROS / oxidative stress Oxidative stress tone ↓ (often); ROS direction can vary by model ROS injury ↓ P, R, G Redox buffering (context-dependent) EA is widely characterized as antioxidant/anti-inflammatory; in cancer models, oxidative stress effects can be secondary to pathway reprogramming.
7 Invasion / metastasis programs (MMPs / EMT) MMPs ↓; migration/invasion ↓ (reported) ↔ G Anti-invasive phenotype Often reported as downstream outcomes tied to NF-κB and survival signaling changes; keep as “reported” (not universal).
8 Angiogenesis signaling (VEGF & angiogenic outputs) VEGF ↓; angiogenic outputs ↓ (reported) ↔ G Anti-angiogenic support Typically observed as later reductions in pro-angiogenic expression/secretion or angiogenesis assays.
9 One-carbon / microbiome conversion to urolithins (translation driver) Systemic activity often mediated by urolithins (e.g., urolithin A) rather than free EA — — PK / metabolite constraint EA and ellagitannins are transformed by gut microbiota into urolithins, bioavailable metabolites; inter-individual variation in “metabotypes” affects exposure and effects.
10 Bioavailability constraint (oral exposure) Free EA systemic exposure often limited (without formulation / metabolite reliance) — — Translation constraint EA has absorption/metabolism constraints; measuring metabolites (urolithins) is often more informative than EA alone.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/rapid effects; early redox interactions)
  • R: 30 min–3 hr (acute stress-response + transcription signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
Scientific Papers found: Click to Expand⟱
289- ALA,  HCA,  EA,    Cancer Metabolism: Fasting Reset, the Keto-Paradox and Drugs for Undoing
- Analysis, NA, NA
"highlight2" >ACLY↓,
2399- CA,  EA,    Polyphenol-rich diet mediates interplay between macrophage-neutrophil and gut microbiota to alleviate intestinal inflammation
- Review, Col, NA
"highlight2" >eff↝, "highlight2" >eff↑, "highlight2" >Weight↑,
1616- CUR,  EA,    Kinetics of Inhibition of Monoamine Oxidase Using Curcumin and Ellagic Acid
- in-vitro, Nor, NA
"highlight2" >*MAOA↓, "highlight2" >*Dose∅, "highlight2" >Dose?,
1609- CUR,  EA,    Curcumin and Ellagic acid synergistically induce ROS generation, DNA damage, p53 accumulation and apoptosis in HeLa cervical carcinoma cells
- in-vitro, Cerv, NA
"highlight2" >eff↑, "highlight2" >Dose∅, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >P53↑, "highlight2" >P21↑, "highlight2" >BAX↑, "highlight2" >Dose∅,
1618- EA,    A comprehensive review on Ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action
- Review, BC, NA
"highlight2" >TumCCA↑, "highlight2" >TumCMig↓, "highlight2" >TumCI↓, "highlight2" >TumMeta↓, "highlight2" >Apoptosis↑, "highlight2" >TGF-β↓, "highlight2" >SMAD3↓, "highlight2" >CDK6↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >angioG↓, "highlight2" >VEGFR2↓, "highlight2" >MAPK↓, "highlight2" >NEDD9↓, "highlight2" >NF-kB↓, "highlight2" >eff↑, "highlight2" >eff↑, "highlight2" >RadioS↑, "highlight2" >ChemoSen↑, "highlight2" >DNAdam↑, "highlight2" >eff↑, "highlight2" >*toxicity∅, "highlight2" >*toxicity∅,
4832- EA,    Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid
"highlight2" >*antiOx↑, "highlight2" >*AntiCan↑, "highlight2" >TumCMig↓, "highlight2" >angioG↓, "highlight2" >ChemoSen↑, "highlight2" >RadioS↑, "highlight2" >*chemoP↑, "highlight2" >*BioAv↓, "highlight2" >eff↓, "highlight2" >selectivity↑, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >VEGF↓, "highlight2" >TumCCA↑, "highlight2" >Apoptosis↑, "highlight2" >ROS↑, "highlight2" >BioAv↑,
4341- EA,    Novel Bioactivity of Ellagic Acid in Inhibiting Human Platelet Activation
- in-vitro, NA, NA
"highlight2" >*AntiAg↑, "highlight2" >*AntiAg↑,
4255- EA,    Effects of nutritional interventions on BDNF concentrations in humans: a systematic review
- Review, NA, NA
"highlight2" >*BDNF↑,
4254- EA,    Chronic administration of ellagic acid improved the cognition in middle-aged overweight men
- Human, Obesity, NA
"highlight2" >*LDL↓, "highlight2" >*HDL↑, "highlight2" >*BDNF↑, "highlight2" >*cognitive↑,
4253- EA,    The effects of Ellagic acid supplementation on neurotrophic, inflammation, and oxidative stress factors, and indoleamine 2, 3-dioxygenase gene expression in multiple sclerosis patients with mild to moderate depressive symptoms: A randomized, triple-blind, placebo-controlled trial
- Human, MS, NA - NA, IBD, NA
"highlight2" >*Mood↑, "highlight2" >*BDNF↑, "highlight2" >*5HT↑, "highlight2" >*antiOx↑, "highlight2" >*Inflam↓, "highlight2" >*AntiCan↑, "highlight2" >*QoL↑, "highlight2" >*neuroP↑, "highlight2" >*cognitive↑, "highlight2" >*memory↑,
4252- EA,    Effect of ellagic acid on BDNF/PI3K/AKT-mediated signaling pathways in mouse models of depression
- in-vivo, NA, NA
"highlight2" >*BDNF↑, "highlight2" >*p‑AKT1↑,
3756- EA,    Acetylcholinesterase and monoamine oxidase-B inhibitory activities by ellagic acid derivatives isolated from Castanopsis cuspidata var. sieboldii
- Analysis, AD, NA
"highlight2" >*AChE↓, "highlight2" >*BACE↓, "highlight2" >*MAOB↓,
2402- EA,    Ellagic Acid and Its Metabolites as Potent and Selective Allosteric Inhibitors of Liver Pyruvate Kinase
- in-vitro, NA, NA
"highlight2" >PKL↓,
1037- EA,    Unripe Black Raspberry (Rubus coreanus Miquel) Extract and Its Constitute, Ellagic Acid Induces T Cell Activation and Antitumor Immunity by Blocking PD-1/PD-L1 Interaction
- in-vivo, CRC, NA
"highlight2" >AntiTum↑, "highlight2" >PD-L1↓,
1621- EA,    The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art
- Review, Var, NA
"highlight2" >AntiCan↑, "highlight2" >Apoptosis↑, "highlight2" >TumCP↓, "highlight2" >TumMeta↓, "highlight2" >TumCI↓, "highlight2" >TumAuto↑, "highlight2" >VEGFR2↓, "highlight2" >MAPK↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >PD-1↓, "highlight2" >NOTCH↓, "highlight2" >PCNA↓, "highlight2" >Ki-67↓, "highlight2" >cycD1/CCND1↓, "highlight2" >CDK2↑, "highlight2" >CDK6↓, "highlight2" >Bcl-2↓, "highlight2" >cl‑PARP↑, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >DR4↑, "highlight2" >DR5↑, "highlight2" >Snail↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >TGF-β↑, "highlight2" >PKCδ↓, "highlight2" >β-catenin/ZEB1↓, "highlight2" >SIRT1↓, "highlight2" >HO-1↓, "highlight2" >ROS↑, "highlight2" >CHOP↑, "highlight2" >Cyt‑c↑, "highlight2" >MMP↓, "highlight2" >OCR↓, "highlight2" >AMPK↑, "highlight2" >Hif1a↓, "highlight2" >NF-kB↓, "highlight2" >E-cadherin↑, "highlight2" >Vim↓, "highlight2" >EMT↓, "highlight2" >LC3II↑, "highlight2" >CIP2A↓, "highlight2" >GLUT1↓, "highlight2" >PDH↝, "highlight2" >MAD↓, "highlight2" >LDH↓, "highlight2" >GSTs↑, "highlight2" >NOTCH↓, "highlight2" >survivin↓, "highlight2" >XIAP↓, "highlight2" >ER Stress↑, "highlight2" >ChemoSideEff↓, "highlight2" >ChemoSen↑,
1620- EA,  Rad,    Radiosensitizing effect of ellagic acid on growth of Hepatocellular carcinoma cells: an in vitro study
- in-vitro, Liver, HepG2
"highlight2" >ROS↑, "highlight2" >P53↑, "highlight2" >TumCCA↑, "highlight2" >IL6↓, "highlight2" >COX2↓, "highlight2" >TNF-α↓, "highlight2" >MMP↓, "highlight2" >angioG↓, "highlight2" >MMP9↓, "highlight2" >BAX↑, "highlight2" >Casp3↑, "highlight2" >Apoptosis↑, "highlight2" >RadioS↑, "highlight2" >TBARS↑, "highlight2" >GSH↓, "highlight2" >Bax:Bcl2↑, "highlight2" >p‑NF-kB↓, "highlight2" >p‑STAT3↓,
1619- EA,  CUR,    Antimutagenic Effect of the Ellagic Acid and Curcumin Combinations
- in-vitro, Nor, NA
"highlight2" >eff↑,
1605- EA,    Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence
- Review, Var, NA
"highlight2" >*BioAv↓, "highlight2" >antiOx↓, "highlight2" >Inflam↓, "highlight2" >TumCP↓, "highlight2" >TumCCA↑, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE/CCNE↓, "highlight2" >P53↑, "highlight2" >P21↑, "highlight2" >COX2↓, "highlight2" >NF-kB↓, "highlight2" >Akt↑, "highlight2" >NOTCH↓, "highlight2" >CDK2↓, "highlight2" >CDK6↓, "highlight2" >JAK↓, "highlight2" >STAT3↓, "highlight2" >EGFR↓, "highlight2" >p‑ERK↓, "highlight2" >p‑Akt↓, "highlight2" >p‑STAT3↓, "highlight2" >TGF-β↓, "highlight2" >SMAD3↓, "highlight2" >CDK6↓, "highlight2" >Wnt/(β-catenin)↓, "highlight2" >Myc↓, "highlight2" >survivin↓, "highlight2" >CDK8↓, "highlight2" >PKCδ↓, "highlight2" >tumCV↓, "highlight2" >RadioS↑, "highlight2" >eff↑, "highlight2" >MDM2↓, "highlight2" >XIAP↓, "highlight2" >p‑RB1↓, "highlight2" >PTEN↑, "highlight2" >p‑FAK↓, "highlight2" >Bax:Bcl2↑, "highlight2" >Bcl-xL↓, "highlight2" >Mcl-1↓, "highlight2" >PUMA↑, "highlight2" >NOXA↑, "highlight2" >MMP↓, "highlight2" >Cyt‑c↑, "highlight2" >ROS↑, "highlight2" >Ca+2↝, "highlight2" >Endoglin↑, "highlight2" >Diablo↑, "highlight2" >AIF↑, "highlight2" >iNOS↓, "highlight2" >Casp9↑, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >RadioS↑, "highlight2" >Hif1a↓, "highlight2" >HO-1↓, "highlight2" >HO-2↓, "highlight2" >SIRT1↓, "highlight2" >selectivity↑, "highlight2" >Dose∅, "highlight2" >NHE1↓, "highlight2" >Glycolysis↓, "highlight2" >GlucoseCon↓, "highlight2" >lactateProd↓, "highlight2" >PDK1?, "highlight2" >PDK1?, "highlight2" >ECAR↝, "highlight2" >COX1↓, "highlight2" >Snail↓, "highlight2" >Twist↓, "highlight2" >cMyc↓, "highlight2" >Telomerase↓, "highlight2" >angioG↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >VEGF↓, "highlight2" >Dose↝, "highlight2" >PD-L1↓, "highlight2" >eff↑, "highlight2" >SIRT6↑, "highlight2" >DNAdam↓,
1617- EA,  CUR,    The inhibition of human glutathione S-transferases activity by plant polyphenolic compounds ellagic acid and curcumin
- in-vitro, Nor, NA
"highlight2" >Dose∅, "highlight2" >GSTs↓,
27- EA,    Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice
- in-vivo, PC, PANC1
"highlight2" >HH↓, "highlight2" >Gli1↓, "highlight2" >GLI2↓, "highlight2" >CDK1/2/5/9↓, "highlight2" >p‑Akt↓, "highlight2" >NOTCH1↓, "highlight2" >Shh↓, "highlight2" >Snail↓, "highlight2" >E-cadherin↑, "highlight2" >NOTCH3↓, "highlight2" >HEY1↓, "highlight2" >TumCG↓, "highlight2" >TumCP↓, "highlight2" >Casp3↑, "highlight2" >cl‑PARP↑, "highlight2" >Bcl-2↓, "highlight2" >cycD1/CCND1↓, "highlight2" >CDK2↓, "highlight2" >CDK6↓, "highlight2" >BAX↑, "highlight2" >COX2↓, "highlight2" >Hif1a↓, "highlight2" >VEGF↓, "highlight2" >VEGFR2↓, "highlight2" >IL6↓, "highlight2" >IL8↓, "highlight2" >MMP2↓, "highlight2" >MMP9↓, "highlight2" >NA↓,
1615- EA,    Absorption, metabolism, and antioxidant effects of pomegranate (Punica granatum l.) polyphenols after ingestion of a standardized extract in healthy human volunteers
- Human, Nor, NA
"highlight2" >*BioAv∅, "highlight2" >*ROS∅,
1614- EA,    Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice
- Human, Nor, NA
"highlight2" >*BioEnh↝, "highlight2" >*Half-Life∅,
1613- EA,    Ellagitannins in Cancer Chemoprevention and Therapy
- Review, Var, NA
"highlight2" >ROS↑, "highlight2" >angioG↓, "highlight2" >ChemoSen↑, "highlight2" >BAX↑, "highlight2" >Bak↑, "highlight2" >Bcl-2↓, "highlight2" >Bcl-xL↓, "highlight2" >CDK2↓, "highlight2" >CDK4↓, "highlight2" >CDK6↓, "highlight2" >cycD1/CCND1↓, "highlight2" >cycE1↓, "highlight2" >TumCG↓, "highlight2" >VEGF↓, "highlight2" >Hif1a↓, "highlight2" >eff↑, "highlight2" >COX2↓, "highlight2" >TumCCA↑, "highlight2" >selectivity↑, "highlight2" >Wnt/(β-catenin)↓, "highlight2" >*toxicity∅,
1612- EA,    Negative Effect of Ellagic Acid on Cytosolic pH Regulation and Glycolytic Flux in Human Endometrial Cancer Cell
- in-vitro, EC, NA
"highlight2" >NHE1↓, "highlight2" >i-pH↓, "highlight2" >ROS↓, "highlight2" >GlucoseCon↓, "highlight2" >NHE1↓, "highlight2" >Glycolysis↓,
1611- EA,    Targeting Myeloperoxidase Activity and Neutrophil ROS Production to Modulate Redox Process: Effect of Ellagic Acid and Analogues
- in-vitro, Mal, NA
"highlight2" >*BioAv↓, "highlight2" >eff↑, "highlight2" >*BioAv↓, "highlight2" >ROS↑,
1610- EA,    Anticancer Effect of Pomegranate Peel Polyphenols against Cervical Cancer
- Review, Cerv, NA
"highlight2" >TumCCA↑, "highlight2" >STAT3↓, "highlight2" >P21↑, "highlight2" >IGFBP7↑, "highlight2" >Akt↓, "highlight2" >mTOR↓, "highlight2" >ROS↑, "highlight2" >DNAdam↑, "highlight2" >P53↑, "highlight2" >P21↑, "highlight2" >BAX↑,
1110- EA,  GEM,    Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters
- vitro+vivo, Bladder, NA
"highlight2" >TGF-β↓, "highlight2" >SMAD2↓, "highlight2" >SMAD3↓, "highlight2" >SMAD4↓,
1608- EA,    Ellagic Acid from Hull Blackberries: Extraction, Purification, and Potential Anticancer Activity
- in-vitro, Cerv, HeLa - in-vitro, Liver, HepG2 - in-vitro, BC, MCF-7 - in-vitro, Lung, A549 - in-vitro, Nor, HUVECs
"highlight2" >eff↑, "highlight2" >Dose∅, "highlight2" >*BioAv↑, "highlight2" >selectivity↑, "highlight2" >TumCP↓, "highlight2" >Casp↑, "highlight2" >PTEN↑, "highlight2" >TSC1↑, "highlight2" >mTOR⇅, "highlight2" >Akt↓, "highlight2" >PDK1↓, "highlight2" >E6↓, "highlight2" >E7↓, "highlight2" >DNAdam↑, "highlight2" >ROS↑, "highlight2" >*BioAv↓, "highlight2" >*BioEnh↑, "highlight2" >*Half-Life∅,
1607- EA,    Exploring the Potential of Ellagic Acid in Gastrointestinal Cancer Prevention: Recent Advances and Future Directions
- Review, GC, NA
"highlight2" >STAT3↓, "highlight2" >TumCP↓, "highlight2" >Apoptosis↑, "highlight2" >NF-kB↓, "highlight2" >EMT↓, "highlight2" >RadioS↑, "highlight2" >antiOx↑, "highlight2" >COX1↓, "highlight2" >COX2↓, "highlight2" >cMyc↓, "highlight2" >Snail↓, "highlight2" >Twist↓, "highlight2" >MMP2↓, "highlight2" >P90RSK↓, "highlight2" >CDK8↓, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >TumCCA↑, "highlight2" >Casp8↑, "highlight2" >PCNA↓, "highlight2" >TGF-β↓, "highlight2" >Shh↓, "highlight2" >NOTCH↓, "highlight2" >IL6↓, "highlight2" >ALAT↓, "highlight2" >ALP↓, "highlight2" >AST↓, "highlight2" >VEGF↓, "highlight2" >P21↑, "highlight2" >*toxicity∅, "highlight2" >*Inflam↓, "highlight2" >*cardioP↑, "highlight2" >*neuroP↑, "highlight2" >*hepatoP↑, "highlight2" >ROS↑, "highlight2" >*NRF2↓, "highlight2" >*GSH↑,
1606- EA,    Ellagic acid inhibits proliferation and induced apoptosis via the Akt signaling pathway in HCT-15 colon adenocarcinoma cells
- in-vitro, Colon, HCT15
"highlight2" >TumCP↓, "highlight2" >cycD1/CCND1↓, "highlight2" >Apoptosis↑, "highlight2" >PI3K↓, "highlight2" >Akt↓, "highlight2" >ROS↑, "highlight2" >Casp3↑, "highlight2" >Cyt‑c↑, "highlight2" >Bcl-2↓, "highlight2" >TumCCA↑, "highlight2" >Dose∅, "highlight2" >ALP↓, "highlight2" >LDH↓, "highlight2" >PCNA↓, "highlight2" >P53↑, "highlight2" >Bax:Bcl2↑,
2306- SIL,  CUR,  RES,  EA,    Identification of Natural Compounds as Inhibitors of Pyruvate Kinase M2 for Cancer Treatment
- in-vitro, BC, MDA-MB-231
"highlight2" >PKM2↓, "highlight2" >Dose↝, "highlight2" >Dose↝,

Showing Research Papers: 1 to 31 of 31

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 31

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 2,   GSH↑, 1,   HDL↑, 1,   NRF2↓, 1,   ROS∅, 1,  

Core Metabolism/Glycolysis ⓘ

p‑AKT1↑, 1,   LDL↓, 1,  

Migration ⓘ

AntiAg↑, 2,  

Immune & Inflammatory Signaling ⓘ

Inflam↓, 2,  

Synaptic & Neurotransmission ⓘ

5HT↑, 1,   AChE↓, 1,   BDNF↑, 4,   MAOA↓, 1,  

Protein Aggregation ⓘ

BACE↓, 1,   MAOB↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 5,   BioAv↑, 1,   BioAv∅, 1,   BioEnh↑, 1,   BioEnh↝, 1,   Dose∅, 1,   Half-Life∅, 2,  

Functional Outcomes ⓘ

AntiCan↑, 2,   cardioP↑, 1,   chemoP↑, 1,   cognitive↑, 2,   hepatoP↑, 1,   memory↑, 1,   Mood↑, 1,   neuroP↑, 2,   QoL↑, 1,   toxicity∅, 4,  
Total Targets: 32

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:74  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page